The olfactory bulbectomized rat as a model of depression: The hippocampal pathway

• Published in: Behavioural brain research 2017-01, Vol.317, p.562-575
• Main Authors: Morales-Medina, J.C., Iannitti, T., Freeman, A., Caldwell, H.K.
• Format: Article
• Language: English
• Subjects: Animal model; Animals; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antidepressive Agents - therapeutic use; Curcumin - therapeutic use; Depression; Depression - drug therapy; Disease Models, Animal; Hippocampus; Hippocampus - drug effects; Hippocampus - physiology; Indans - therapeutic use; Long-Term Potentiation - drug effects; Neurogenesis - drug effects; Neurogenesis - physiology; OBX; Olfactory Bulb - physiology; Olfactory Bulb - surgery; Olfactory bulbectomy; Rats; Spiro Compounds - therapeutic use
• ISSN: 0166-4328; 1872-7549
• DOI: 10.1016/j.bbr.2016.09.029

•Olfactory bulbectomy is a model of major cellular dysfunction in the hippocampus.•Olfactory bulbectomy (OBX) induces behavioral deficits similar to clinical depression.•Imipramine and curcumin reduce hippocampal neuroinflammation in OBX rats.•Citalopram and ZSET1446 improve dentate gyrus neurogenesis in OBX rats.•Nefiracetam, sunifiram and rivastigmine restore LTP in CA1 hippocampus in OBX rats. In rodents, the removal of the olfactory bulbs (OBs), i.e. olfactory bulbectomy (OBX), results in numerous alterations in neurotransmitter, endocrine and immune systems, as well as behavioral changes, similar to those observed in depressed patients. Because the behavioral deficits induced in OBX animals are reversed after repeated administration of antidepressants, this is a model often used to test the effectiveness of putative antidepressant agents. Recent evidence suggests that OBX results in the dysfunction of various cellular processes within the hippocampus, including decreases in dentate gyrus neurogenesis, disruption in long-term potentiation in CA1 and CA3 subregions and neuronal atrophy in the CA1 subregion, along with downstream markers, all of which are consistent with abnormal neuronal activity in the hippocampus of clinically depressed populations. Moreover, repeated administration of novel natural and synthetic antidepressant compounds can improve certain aspects of depression-like behavior and hippocampal function. In an effort to bring together the existing literature, this review will focus on the mechanisms by which proposed pharmaceuticals impact hippocampal-dependent processes and behavior.